Maverix Medical

What Maverix Medical does

Maverix Medical, LLC is a private lung cancer-focused medical device and diagnostics platform headquartered in Menlo Park, California, founded in November 2023 as a joint venture between Ajax Health, KKR, and Hologic. The company operates three integrated product lines covering the lung cancer care continuum: Thoracent (airway and esophageal nitinol stents, EBUS needles, biopsy forceps, and retrieval nets for interventional pulmonology and gastroenterology), Maverix Diagnostics (blood-based molecular diagnostic tools in development for lung cancer triage and screening), and Serpex (steerable endobronchial instruments including the Compass Steerable Needle and Recon Steerable Sheath designed to reach off-airway peripheral nodules). Core technology includes a patented hook-and-cross nitinol stent architecture that adapts to human anatomy, multiomic diagnostic capabilities acquired through Cirrus Bio, and steerable instruments engineered for compatibility with the dominant robotic bronchoscopy platforms (Intuitive Ion, J&J Monarch, Noah Medical Galaxy, Medtronic Illumisite).

Maverix monetizes through direct B2B enterprise sales of medical devices to interventional pulmonologists, gastroenterologists, and hospitals, with quote-based pricing, overnight shipping, and dedicated customer care support. The company generates revenue primarily through hardware sales of cleared interventional devices (stents, biopsy tools, needles) and is building a future diagnostics revenue stream through one-time or licensed molecular tests. Distribution is handled through direct field sales with no public disclosure of pricing or contract terms. The customer base consists of healthcare providers and hospital systems; no named customer logos or disclosed customer concentration is available.

The platform was assembled through three acquisitions in 18 months (Serpex Medical December 2023, Cirrus Bio March 2024, Thoracent 2025), each contributing a distinct capability to the integrated lung cancer portfolio. Leadership is drawn from Ajax Health's executive bench, with a track record of medtech exits to Boston Scientific, Medtronic, Entellus, and Covidien. The company maintains a Medical Advisory Board of leading pulmonary physicians for clinical validation and peer influence. Revenue is not publicly disclosed, and the company remains in commercial buildout mode with 1-10 employees at the legal entity level.

Name

Maverix Medical

Legal name

Maverix Medical, LLC

Website

https://maverixmedical.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

Maverix Medical is a private lung cancer platform that develops and commercializes interventional pulmonology and gastroenterology devices, blood-based molecular diagnostics, and steerable endobronchial instruments, serving interventional pulmonologists, gastroenterologists, and hospitals across the full lung cancer care continuum.

Ownership category

akta.pro rank

Product category

Interventional Pulmonology Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Laboratories (621511), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Thoracic (Lung) Oncology (HLAKAFAL)

akta.pro secondary industries

Lung Cancer Screening & Pulmonary Nodule Clinic (HLAKANAI), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

Keywords

• Interventional pulmonology devices
• Lung cancer diagnostics
• Bronchoscopy biopsy tools
• Airway stents
• Endobronchial instruments

Headquarters

HQ city

Menlo Park

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device Sales: Sale of interventional pulmonology and gastroenterology devices including stents, biopsy tools, EBUS needles, and retrieval nets. Products sold through direct enterprise sales to healthcare providers.
2. Diagnostic Tools: Development and future sale of molecular diagnostic tools for lung cancer triage and early detection. Currently developing blood-based diagnostic tests to identify high-risk patients.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Maverix Medical develops and sells a portfolio of medical devices and molecular diagnostics for the lung cancer care continuum, spanning screening, biopsy, and palliative treatment. Its product lines include Thoracent (airway and GI stents, EBUS needles, biopsy forceps, retrieval nets), Maverix Diagnostics (blood-based multiomic diagnostics for early lung cancer detection), and the Serpex Steerable Portfolio (steerable endobronchial instruments including the Compass Steerable Needle and Recon Steerable Sheath for reaching off-airway nodules).

Product overview

Maverix Medical is a lung cancer platform that offers a portfolio of medical devices and diagnostics focused on the full spectrum of lung cancer care from screening to treatment. The company's product ecosystem consists of three main product lines: (1) Thoracent — a sub-brand delivering interventional pulmonology and GI products including airway stents (Y-Shaped Tracheal Stent, Bonastent Tracheobronchial Stent, Bonastent Esophageal Stent, Hilzo TTS Esophageal Stent, Hilzo UES Esophageal Stent), EBUS needles, biopsy forceps, and retrieval nets; (2) Maverix Diagnostics — developing blood-based molecular diagnostic tools for lung cancer triage; and (3) Serpex Steerable Portfolio — a suite of steerable endobronchial instruments including Compass Steerable Needle and Recon Steerable Sheath for accessing difficult-to-reach peripheral lung nodules.

Differentiator

Problem solved

Functional benefit

Brands

• Thoracent: Minimally invasive devices for managing pleural effusions and restoring airway patency, including stents, biopsy devices, and GI tools for palliative care.
• Maverix Diagnostics
• Serpex

Products and services

• Thoracent Product Line
• Y-Shaped Tracheal Stent
• Bonastent Tracheobronchial Stent
• Bonastent Esophageal Stent
• Hilzo TTS Esophageal Stent
• Hilzo UES Esophageal Stent
• EBUS Needles (Trident FNB and Areus FNA)
• Biopsy Forceps
• Netis Retrieval Net
• Maverix Diagnostics (Maverix Dx)
• Serpex Steerable Portfolio
• Serpex Compass Steerable Needle
• Serpex Recon Steerable Sheath

Quantifiable outcome

• More than half of stage I lung cancer patients can be cured by a single surgery with early detection and resection
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• Cirrus BiocoreStrategic or Co-development Partner · 29 March 2024Acquired by Maverix Medical to establish a diagnostics platform focused on lung cancer. Cirrus Bio develops multiomic solutions for early detection of diseases. The acquisition introduced Maverix Dx, a dedicated diagnostic division for developing lung cancer diagnostics spanning screening through disease management.
• ThoracentcoreStrategic or Co-development PartnerThoracent was founded in 2017 and acquired by Maverix Medical. The company delivers innovative products for interventional pulmonologists and gastroenterologists, including stents and biopsy devices. Thoracent operates as a Maverix company with its own CEO (Brian Lynch) and CFO (Rebecca Bergin).

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Intuitive Surgical: Maker of the Ion robotic bronchoscopy platform, directly competing with Maverix's Serpex steerable biopsy tools for lung nodule access. Intuitive is a primary channel partner and competitor in interventional pulmonology.
• Johnson & Johnson (Ethicon / Monarch): Sells the Monarch robotic bronchoscopy platform and competes with Maverix's Serpex steerable instruments in the same interventional pulmonology workflow. Also a channel partner through declared compatibility.
• Medtronic: Markets the Illumisite EWC extended working channel and integrated bronchoscopy solutions. Competes with Serpex steerable products and has historical overlap with Ajax portfolio companies that exited to Medtronic.

Emerging players

• Noah Medical: Developer of the Galaxy robotic bronchoscopy system, an emerging competitor in lung nodule biopsy. Galaxy is one of the four platforms that Serpex tools integrate with, making Noah both a channel partner and indirect competitor.
• Biodesix: Commercial-stage lung cancer diagnostics company offering blood-based tests for nodule management. Directly comparable to Maverix Diagnostics in the early lung cancer detection workflow.

Broad incumbents

• Boston Scientific: Major diversified medtech with interventional pulmonology, endoscopic, and pulmonary product lines that overlap with Thoracent stents and biopsy forceps. Also previously acquired Ajax platform company Cortex.
• Olympus Corporation: Dominant bronchoscope manufacturer and a major player in GI endoscopy devices. Maverix Serpex products are explicitly compatible with Olympus P190 bronchoscopes, making Olympus both a complementary incumbent and potential competitor in steerable instruments.
• Cook Medical: Long-established manufacturer of airway stents and pulmonary interventional devices, directly comparable to the Thoracent stent portfolio (Y-Stent, Bonastent, Hilzo).
• Merit Medical Systems: Diversified manufacturer of endoscopy and interventional devices including airway stents and biopsy tools, comparable to the Thoracent product line.
• Guardant Health: Leading blood-based cancer diagnostics company with a multi-cancer and lung-focused pipeline. Represents a scaled, well-capitalized competitor in the lung cancer diagnostic space Maverix is targeting.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/about

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maverix Medical